MAP3K9

Across TCGA pan-cancer cohorts, MAP3K9 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MAP3K9 data layer compared with 6 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher MAP3K9 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K9 expression acts as an unfavorable survival marker, although some lineages such as SCLC and ESCA show a favorable association.

MESO, SCLC, and LIHC are the cancer types where MAP3K9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.224	0.395	.001	81	view →
SCLC	OS	Quartile	All	0.831	0.471	<.001	65	view →
LIHC	OS	Median	All	0.370	0.684	<.001	47	view →
KIRP	OS	Median	III,IV	0.140	0.696	.002	38	view →
DLBC	DFS	Median	III,IV	0.294	0.984	.003	35	view →
READ	DFS	Median	IV	0.359	0.794	.002	27	view →
LAML	DFS	Quartile	All	0.423	0.652	.015	24	view →
KICH	DFS	Median	III,IV	0.337	0.853	.010	21	view →
ACC	DFS	Median	All	0.259	0.629	.002	20	view →
LUSC	DFS	Quartile	III,IV	0.484	0.731	.013	13	view →
SKCM	OS	Median	III,IV	0.642	0.762	.015	13	view →
ESCA	OS	Median	III,IV	0.534	0.308	.019	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MAP3K9–MESO (DFS)

Open the MESO breakdown →